Skip to main content

Table 5 Statistical association between PsAID-12 and MDA

From: Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease

Domains PsAID Non-MDA MDA VLDA p*
Median
(P25-P75)
Median
(P25-P75)
Median
(P25-P75)
Pains 6 (3-8)c 3 (1-5)b 0 (0-0.5)a < 0.001
Fatigue/Tiredness 5 (3-7.8)b 2 (1.5-4.5)a 0 (0-1.5)a < 0.001
Skin Problems 4 (1.3-6.8)b 1 (0-2.5)a 0 (0-3)a < 0.001
Work and/or leisure activity 5 (2-8)b 2 (0-4)a 0 (0-0)a < 0.001
Physical Ability 6 (3-8)b 3 (1-5)a 0.5 (0-1)a < 0.001
Discomfort 5 (3-8)b 2 (0.5-4)a 0 (0-0.3)a < 0.001
Sleep disturbance 3 (0.3-7)b 1 (0-3)ab 0 (0-0)a < 0.001
Dealing with the disease 4.5 (2-6)b 2 (0-3)a 0 (0-1)a < 0.001
Anxiety/Fear/Uncertainty 5 (2.3-8)b 2 (0-4.5)a 0 (0-0.3)a < 0.001
Embarrassment and/or shame 2 (0-5)b 0 (0-1.5)ab 0 (0-0)a < 0.001
Social Participation 2 (0-5.8)b 0 (0-1.5)a 0 (0-0)a < 0.001
Depression 2.5 (0-6)b 1 (0-2)ab 0 (0-0)a < 0.001
Total score 4.7 (3.0-6.4)c 2.2 (1.4-3.6)b 0.5 (0.2-0.9)a < 0.001
Total PsAID ≤4 – n (%) 44 (42.3)a 18 (85.7)b 14 (100)b < 0.001
  1. PsAID Psoriatic Arthritis Impact of Disease, MDA Minimal Disease Activity, VLDA Very Low Disease Activity
  2. *Kruskal-Wallis test; a, b, c Equal letters don’t differ by the Dunn test or residuals adjusted at 5% significance